AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...
The deal, first announced last November, would have resulted in the world's biggest pharma company but was ... so-called tax inversions, of which Pfizer-Allergan was the most controversial and ...
As activist Starboard teams up with former Pfizer executives, the pharma giant’s lack of focus is in the spotlight.
Pfizer's stock is poised for growth with strong technical and fundamental indicators, promising pipeline, and Seagen ...
Fonseca joined Pfizer in 2019, bringing more than 20 years ... My point of view is that pharma as well as other key players in the health care ecosystem will need to work together to provide ...
Pfizer's decision will affect research into drugs for Alzheimer's and Parkinson's disease Drug company Pfizer has announced it is pulling out of research into drugs to treat Alzheimer's disease ...
Bristol Myers Squibb's schizophrenia drug, which received FDA approval last week, took a long and winding road to get there. Three decades ago, Eli Lilly developed the drug's forerunner, xanomeline, ...
Dr. Dolsten expressed enthusiasm about joining Rocket Pharma, noting the company's promising ... Inc. In other recent news, Pfizer Inc. faced a downgrade from "Buy" to "Hold" by Erste Group ...
During her first year, she's homed in on five priorities, generally based around innovating with technology and building a digital culture at Pfizer, a $210 billion pharma company known for the ...
Pfizer (PFE) stock may present opportunities for patient investors. Read how this biotech giant may deliver long-term ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback